


# LTL-424 datasheet

<b>Origin</b>	Primary human ovarian cancer	<b>Histopathology</b>	Serous adenocarcinoma
<b>Year of establishment</b>	2012	<b>Doubling time</b>	14 days (subcutaneous graft site)
<b>Local invasion</b>	Yes, limited	<b>Metastasis</b>	No

The LTL-424 (Fig. 1) was developed from a patient's primary ovarian cancer (high grade serous adenocarcinoma). The LTL-424 grows well at both subcutaneous and subrenal capsule graft sites. The LTL-424 shows limited local invasion but no distant metastasis in host.



**Fig 1. H&E stained LTL-424 tissue sections.**

(A), the tumor cells grow in small nests or form solid sheets (100x). (B), the tumor cells contain round to oval nuclei with fine chromatin and prominent nucleoli (400x).

## Genetic and epigenetic characteristics

Tumor line tissue (in tissue microarrays) for IHC and ISH is in place for screening potential targets upon request.

## Applications

1. Pre-clinical evaluation of existing and potential anticancer drugs. Examination of drug efficacy on tumor growth, cell death (apoptosis, necrosis), tissue invasion, metastasis (in combination with metastatic tumor lines) and angiogenesis.
2. Discovery of potential therapeutic targets and/or biomarkers for drug sensitivity.

3. Study of mechanisms underlying tumor growth, progression and metastasis (in combination with metastatic tumor lines).

**For more information, please contact us by email: [LTL@bccrc.ca](mailto:LTL@bccrc.ca) or phone: (604) 675 8013**